Spinal Cord Injuries: Clinical Trials

220 trials for Spinal Cord Injuries, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

120 completed, 36 unknown, 21 terminated, 18 recruiting. 220 Phase 2, 69 Phase 1, 31 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2220Completed 120, Unknown 36, Terminated 21, Recruiting 18, Not yet recruiting 9, Withdrawn 8, Active not recruiting 6, Suspended 2
Phase 169Completed 36, Unknown 15, Recruiting 7, Not yet recruiting 6, Terminated 3, Withdrawn 2
Phase 331Completed 17, Recruiting 4, Terminated 4, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Suspended 1, Withdrawn 1

Follow Spinal Cord Injuries: new trials by email Literature Review of Spinal Cord Injuries trials Research Report on Spinal Cord Injuries

Trials (filtered) newest first · largest first

All 220 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Device for Bladder Control for Men With SCI
Noninvasive electrical stimulation device to improve bladder control - Neurogenic Bladder
Phase 1 / Phase 2Not yet recruitingVA Office of Research and Development122028-06-012026-06-25
Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells, Placebo - Spinal Cord Injury, Safety
Phase 2Not yet recruitingXellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.602028-05-252025-11-25
Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial
testosterone cypionate, finasteride, placebo injection - Spinal Cord Injury, Spinal Cord Injuries
Phase 2 / Phase 3Not yet recruitingVA Office of Research and Development3002027-10-012026-08-04
Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury
Istradefylline, low oxygen therapy - Spinal Cord Injuries, Myelopathy
Phase 1 / Phase 2Not yet recruitingRandy Trumbower, PT, PhD402027-09-012026-03-20
NO AD: Use of Nitric Oxide (NO) Donors for the Prevention of Autonomic Dysreflexia (AD) During Bowel Care Following SCI
Glyceryl Trinitrate Only Product in Oromucosal Dose Form, Placebo sublingual spray - Spinal Cord Injuries, Autonomic Dysreflexia
Phase 2Not yet recruitingSimon Fraser University262026-12-012026-04-23
Pilot Testing of Vagus Nerve Stimulation for Early Spinal Cord Injury Recovery
Transauricular vagus nerve stimulation - Spinal Cord Injuries (Complete and Incomplete)
Phase 1 / Phase 2Not yet recruitingUniversity of Alabama at Birmingham502026-11-012026-08-05
Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)
Galantamine Hydrobromide Extended Release - Spinal Cord Injury, Traumatic Spinal Cord Injury
Phase 2 / Phase 3RecruitingNorthwell Health602026-10-152026-11-04
Extracorporeal Shockwave Therapy as an Additional Treatment for Spasticity Secondary to Spinal Cord Injury
Focused extracorporeal shockwave therapy, Botulinum toxin, Sham - Spinal Cord Injury, Spasticity
Phase 2RecruitingKessler Foundation302026-09-212026-11-04
Psilocybin to Treat Depression in Spinal Cord Injury
Psilocybin (Usona Institute) - Spinal Cord Injury, Depression - Major Depressive Disorder
Phase 1 / Phase 2RecruitingJames J. Peters Veterans Affairs Medical Center302026-08-062026-08-10
Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy
Urodynamics, EG110A, Patient-reported Outcome - Urinary Bladder, Overactive, Spinal Cord Injury
Phase 1 / Phase 2Not yet recruitingCyllene Therapeutics162026-04-012025-11-12
CE-STAND: Cervical Epidural STimulation After Neurologic Damage
Epidural Spinal Cord Stimulation System - Spinal Cord Injury
Phase 1 / Phase 2RecruitingUniversity of Minnesota362026-03-152026-03-27
CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury
CBD - Supra-sacral Spinal Cord Injury, Spinal Cord Injury
Phase 2RecruitingUniversity of Wisconsin, Madison202026-02-132026-09-16
Improving Walking After Spinal Cord Injury
Paired Associative Stimulation, Locomotor Training, Sham stimulation - Spinal Cord Injury
Phase 1 / Phase 2Not yet recruitingShirley Ryan AbilityLab202025-11-152025-11-03
Improving 24-hour Blood Pressure Stability in Spinal Cord Injury With Low Oxygen Therapy
Low oxygen therapy (LOT) - Spinal Cord Injury
Phase 1 / Phase 2RecruitingGlen Foster102025-10-232025-11-18
Guttmann NeuroRecovery - Viability, Safety, and Efficacy of Intrathecal Wharton's Jelly Mesenchymal Stem Cells and Transcutaneous Spinal Cord Stimulation in Chronic Spinal Cord Injury Rehabilitation
Allogeneic Wharton's jelly mesenchymal stem cells (WJ-MSCs) - Spinal Cord Injuries (SCI), Spinal Cord Injury
Phase 1 / Phase 2Not yet recruitingInstitut Guttmann102025-09-012025-05-25
Paired Stimulation Plasticity for Motor Recovery in Humans With and Without Spinal Cord Injury
CST PAS, RST PAS, sham PAS - Healthy Control, Spinal Cord Injury
Phase 2RecruitingShirley Ryan AbilityLab3002025-08-282026-10-14
First-in-Human Clinical Trial of STUP-001, an In Vivo Direct Cell Conversion Gene Therapy for AIS-A/B Chronic Spinal Cord Injury
STUP-001 - Spinal Cord Injury, Chronic Spinal Cord Injury
Phase 1 / Phase 2RecruitingYonsei University92025-07-302025-07-16
Effects of CBD/CBD-A Oral Extract on Resting-state EEG and Neuropathic Pain Symptoms After SCI
CBD/CBD-A, Placebo - SCI - Spinal Cord Injury, Neuropathic Pain
Phase 1 / Phase 2CompletedUniversity of Miami62025-06-162026-08-14
Double Dose 4-AP on Functional Recovery After Spinal Cord Injury
Dalfampridine, Placebo, STDP stimulation - SCI - Spinal Cord Injury
Phase 1 / Phase 2RecruitingShirley Ryan AbilityLab272025-02-012026-06-03
Treating Central Neuropathic Pain With Low Dose Naltrexone for People With Spinal Cord Injury
4.5mg daily dose of naltrexone - Central Neuropathic Pain, Spinal Cord Injury
Phase 2CompletedMedical College of Wisconsin112025-02-012026-11-02

Showing 20 of 220. Sign in to see all of them.

Narrower conditions

Quadriplegia (19)  ·  Paraplegia (14)  ·  Spinal Cord Diseases (12)  ·  Urinary Bladder, Neurogenic (10)  ·  Wounds and Injuries (10)  ·  Neuralgia (9)  ·  Osteoporosis (8)  ·  Bone Diseases, Metabolic (6)  ·  Central Nervous System Diseases (6)  ·  Chronic Pain (6)  ·  Nervous System Diseases (6)  ·  Neurologic Manifestations (6)  ·  Paralysis (6)  ·  Agnosia (5)

Broader conditions

Central Nervous System Diseases (214)  ·  Nervous System Diseases (214)  ·  Trauma, Nervous System (213)  ·  Wounds and Injuries (210)  ·  Spinal Cord Diseases (208)  ·  Pathological Conditions, Signs and Symptoms (80)  ·  Signs and Symptoms (76)  ·  Neurologic Manifestations (57)  ·  Male Urogenital Diseases (21)  ·  Urogenital Diseases (21)  ·  Female Urogenital Diseases (19)  ·  Female Urogenital Diseases and Pregnancy Complications (19)  ·  Urologic Diseases (19)  ·  Paralysis (18)  ·  Pain (15)

Interventions

Sodium Chloride (6)  ·  Botulinum Toxins, Type A (4)  ·  Buspirone (4)  ·  Lithium Carbonate (4)  ·  Midodrine (4)  ·  Resistance Training (4)  ·  Cholecalciferol (3)  ·  Methylprednisolone (3)  ·  NG-Nitroarginine Methyl Ester (3)  ·  Transcranial Direct Current Stimulation (3)  ·  Vitamin D (3)  ·  mirabegron (3)  ·  salicylhydroxamic acid (3)  ·  4-Aminopyridine (2)  ·  Alendronate (2)

Sponsors

US Department of Veterans Affairs (13)  ·  VA Office of Research and Development (13)  ·  Kessler Foundation (8)  ·  James J. Peters Veterans Affairs Medical Center (7)  ·  China Spinal Cord Injury Network (5)  ·  Brigham and Women's Hospital (4)  ·  Medstar Health Research Institute (4)  ·  Northwestern University (4)  ·  Shirley Ryan AbilityLab (4)  ·  Spaulding Rehabilitation Hospital (4)  ·  University of Alberta (4)  ·  University of British Columbia (4)  ·  Chinese Academy of Sciences (3)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (3)  ·  Hugo W. Moser Research Institute at Kennedy Krieger, Inc. (3)

Countries

United States (129)  ·  Canada (24)  ·  China (17)  ·  Spain (12)  ·  South Korea (7)  ·  Switzerland (6)  ·  Australia (5)  ·  India (5)  ·  Japan (4)  ·  Germany (3)  ·  Jordan (3)  ·  Russia (3)  ·  Taiwan (3)  ·  Brazil (2)  ·  Denmark (2)

Top investigators

Nancy Rocheleau, Program Analyst (5)  ·  Thomas J Schnitzer, MD, PhD (5)  ·  John Fryer, Ph.D. Asst. Director (4)  ·  Ashraf Gorgey, PhD PT (3)  ·  Jessica D'Amico, PhD (3)  ·  Limin Rong, M.D. (3)  ·  Trevor A. Dyson-Hudson, M.D. (3)  ·  William Bauman, MD (3)  ·  Antonio Oliviero, MD, PhD (2)  ·  Ashraf S Gorgey, PhD (2)  ·  Christine N. Sang, MD, MPH (2)  ·  Cornelia Haag-Molkenteller, MD (2)  ·  Cristina L Sadowsky, MD (2)  ·  Hui Zhu, MD (2)  ·  Jeanne M Zanca, PhD, MPT (2)

Results publications

PMID 21762873, PMID 30334093, PMID 36875669, PMID 10569435, PMID 15663976, PMID 16398945, PMID 16793729, PMID 17046161, PMID 17385265, PMID 17475549, PMID 17965289, PMID 19618698, PMID 19648013, PMID 19651280, PMID 19799783, PMID 19903102, PMID 19996767, PMID 20012982, PMID 20418657, PMID 20801263, PMID 21252493, PMID 21303266, PMID 21372246, PMID 21381984, PMID 21717386, PMID 21949432, PMID 22105463, PMID 22232031, PMID 22505632, PMID 22525310, PMID 22985379, PMID 23295632, PMID 23343764, PMID 23452836, PMID 23532434, PMID 23700789, PMID 23844986, PMID 24401143, PMID 24824524, PMID 24968251, PMID 24987412, PMID 25209445, PMID 26394202, PMID 26705884, PMID 26828618, PMID 27901413, PMID 28864949, PMID 28948164, PMID 29244816, PMID 30467135

NIH funding

2016 (2), R01NS041503 (2), 1IK2CX000547 (1), 2014 (1), 2018 (1), 2019 (1), 2025 (1), I01RX001449 (1), I01RX003415 (1), I21RX004417 (1), P30CA016672 (1), R01DA030424 (1), R01HD081274 (1), R01HD093724 (1), R01HD103904 (1)